Hingge Hsu | Senior Advisor, Catalysis Capital

He is senior advisor to Catalysis Capital, international venture capitalist, investment banker, and corporate and business development executive. He has more than 25 years of experience in venture capital, investment bank and business development. He was the managing director of Lehman Brothers Private Equity Group and a partner at Fidelity Biotech Ventures. In addition, he has served as a member of board of directors on a number of private bio-pharmaceutical and medical device company. He earned an MD from Yale University School of Medicine and an MBA from Harvard Business School.


Judith J. Li | Partner, Lilly Asia Ventures

Judith J. Li, is a Partner at Lilly Asia Ventures (LAV), based in Hong Kong / Shanghai and focused on early and growth stage investments across biopharmaceuticals, medical devices, and diagnostics both domestically and cross-border. Judith holds board appointments at a variety of LAV’s portfolio companies including Nextcure, Crown Biosciences, Hangzhou Just Biotherapeutics, and Veritas Genetics. Her prior experience includes McKinsey’s New York office, hospital administration at Partners Healthcare, and co-founding an interventional nephrology medical device venture. Judith holds a B.A. in Neurobiology from Harvard and M.B.A. from Harvard Business School, and currently resides in Hong Kong, splitting her time between Hong Kong, Shanghai, and the Bay Area.


Robert Nelsen | Co-founder and Managing Director, ARCH Venture Partners

As Co-founder and a Managing Director of ARCH Venture Partners, He has invested in several biotechnology leader, and now worked as board director of Agios Pharmaceuticals, Juno Therapeutics, Denali Therapeutics, Sage Therapeutics, Syros Pharmaceuticals as well as Chairman of the board of Hua Medicine. He was the director of the Fred Hutchinson Cancer Research Center at the Institute of System Biology and a member of the American Venture Capital Association, the Fred Hutchinson Cancer Institute, the Institute of Systems Biology and the National Venture Capital Association. He has been selected as the world's top 100 creative investors, and ranked first in the field of biotechnology investors. He has an MBA from University of Chicago.

Jim Thomas | Chief Executive Officer, Just US

As founding partner and CEO of Just US, Jim has over 30 years of experience in biotechnology and scientific leadership. Previously, Jim served as vice president of Process and Product Development at Amgen. In this role, he led the development and application of all process, analytical and formulation technologies used to manufacture both clinical and commercial large molecule products. He worked as a scientist and leader at Genentech, Immunex and Amgen. Over the course of his career, he has contributed to the advancement of many important therapeutics including Activase®, Vectibix®, Enbrel®, Prolia®/Xgeva® and Repatha™.

Jonathan Zhao | Co-Founder and Chief Executive Officer, Hangzhou Just Biotherapeutics

Dr. Jonathan Zhao brings his 17 years’ biopharmaceutical experience in the areas of Strategy Management, Business Development, Product Development and M&A. Dr. Zhao started his pharmaceutical career at Amgen in 1999, then joined Pfizer in 2004 and returned to Amgen in 2012. He was Executive Strategy Director at Global Commercial Operations of Amgen based in Thousand Oaks, California where he was leading the market entry strategy, business development and commercialization of biosimilars in 20 countries outside US and EU. When at Pfizer, he was the Asia Strategy Lead overseeing the Asia strategy across small molecule, biologics and vaccine. He had also served as the interim head of Pfizer’s Bio-enhancement Development Unit during 2009-2010 in charge of the biosimilar and biobetter strategy development and business operation.

Dr. Zhao received his B.S. in Pharmaceutical Sciences from Fudan University (Shanghai, China), Ph.D. magna cum laude in Analytical Chemistry from Ghent University (Ghent, Belgium), and MBA from Massachusetts Institute of Technology (Cambridge, USA). Jonathan has contributed more than 30 peer-reviewed publications and book chapters.

Khoo Shih | Managing Director, Temasek International

Ms. Khoo Shih joined Temasek in 2007 and is currently managing director in the investment group. Prior to Temasek, Khoo Shih was Investment Manager with UOB Venture Management Pte Ltd, primarily focusing on Life Science and healthcare related investment activities. Before UOB, she was the Assistant Head, Biomedical Sciences with Singapore Economic Development Board. Khoo Shih began her career with Singapore General Hospital as a Research Scientist in Department of Clinical Research. She received her Ph.D. in Genetics and Development from University of Texas Southwestern Medical Center.

Hao Ren | Executive Director, Taikang Asset Management

As Executive Director at Taikang Asset Management, Mr. Hao Ren is responsible for investing equity investment projects and funds in the pharmaceutical sector; he is a Board Member of two medical companies that Taikang has invested. He is also a Member of the Advisory Board of several top-notch equity investment funds in the country. Mr. Ren earned an MBA from Peking University.